Quote:
Originally Posted by wordsmithy
I have found that business and finance, rather than science, gives a more sober prediction of what's in the pipeline for PD.
In 2007, I jotted down some notes from "Pharmaceutical Business Review":
"The following drugs are expected to do well in the next 10 years:
Novartis's Stalevo
GSK's Requip Modutab
UCB Schwartz's Neupro
"Although cell/gene therapies show great promise, these approaches will not signficantly impact the sale of pharmaceuticals over the period 2007-2016."
|
i have never used neupro and forget what it is. is it on the market yet?the others cause dyskineisa for me and stalevo is very expensive.Has the price come down any? i was told by my pharmacy the first time i ordered stalevo, i saved more than $600 with insurance.
pharma doesn't need to crunch the numbers about people who improved or who died . that doesn't pay the salaries.
my alprazolam [generic xanax] is less than $8. stalevo $800